Septal Myectomy and Concomitant Coronary Artery Bypass Grafting for Patients With Hypertrophic Cardiomyopathy and

Anita Nguyen1, Hartzell V Schaff1, Ahmed F Sedeek1

  • 1Department of Cardiovascular Surgery, Mayo Clinic, Rochester, MN.

Insights

Patients with hypertrophic cardiomyopathy undergoing septal myectomy and coronary artery bypass grafting (CABG) face increased mortality risk. This study highlights CABG as a significant predictor of late death in these complex cases.

Area of Science:

  • Cardiology
  • Cardiac Surgery
  • Clinical Outcomes

Background:

  • Severe coronary artery disease (CAD) increases mortality in hypertrophic cardiomyopathy (HCM) patients.
  • Limited data exists on the long-term impact of coronary revascularization during septal myectomy.

Purpose of the Study:

  • To evaluate the effect of concomitant coronary artery bypass grafting (CABG) on mortality in patients undergoing transaortic septal myectomy for HCM.
  • To identify risk factors for mortality in this patient population.

Main Methods:

  • Retrospective analysis of 2913 adult patients undergoing septal myectomy between 1961 and 2017.
  • Comparison of baseline characteristics and outcomes between patients with and without concomitant CABG.
  • Multivariable analysis to identify independent predictors of all-cause mortality.

Main Results:

  • Concomitant CABG was performed in 8.4% of patients and was associated with older age and male sex.
  • Operative mortality was higher in the CABG group (2.2% vs 0.8%).
  • Multivariable analysis identified concomitant CABG (HR 1.89), older age, atrial fibrillation, diabetes, higher BMI, and earlier surgery as mortality risk factors.

Conclusions:

  • Obstructive coronary artery disease requiring CABG during septal myectomy is a significant risk factor for late mortality in HCM patients.
  • Careful patient selection and risk stratification are crucial for those requiring combined procedures.

Related Concept Videos

Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
213
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
246
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
297
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
361
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
375
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
188